Mizuho analyst Anthony Petrone lowered the firm’s price target on Abbott (ABT) to $125 from $140 and keeps a Neutral rating on the shares following the Q4 report. The firm cut estimates following the print. With the most recent Nutritional setback, the call for portfolio repositioning is now back in focus, which presents optionality moving forward for the shares, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target lowered to $135 from $150 at Piper Sandler
- Abbott price target lowered to $125 from $154 at Bernstein
- Abbott price target lowered to $140 from $155 at Citi
- Abbott price target lowered to $122 from $146 at Wells Fargo
- Buy Rating on Abbott: Near‑Term Nutrition Headwinds Offset by High-Growth MedTech and Attractive 2026 Valuation